Key Findings
Asahi Kasei, a leading Japanese chemical company, has installed a novel forward osmosis–membrane distillation (FO-MD) system at Peptistar’s API manufacturing facility. This implementation aims to revolutionize the production process for thermolabile active pharmaceutical ingredients (APIs), particularly peptides and oligonucleotides, promising dramatically reduced manufacturing times and lower energy consumption.
Technical/Clinical Details
The forward osmosis–membrane distillation (FO-MD) system offers a distinct advantage over conventional heat-intensive concentration and drying processes like evaporation or lyophilization. FO-MD utilizes a draw solution with high osmotic pressure to efficiently extract water molecules from the target liquid (in this case, an API solution) without applying external heat or pressure. This capability is critical for delicate molecules like peptides and oligonucleotides, which are highly sensitive to heat, allowing for safe and efficient dehydration and concentration with minimal risk of degradation. The integration of this system at Peptistar’s API manufacturing facility is projected to significantly reduce the number of batches and processing time required for lyophilization during the concentration step. As lyophilization is a time- and energy-intensive process, its efficiency improvement directly translates into reduced manufacturing costs. Currently, the FO-MD system is undergoing evaluation at manufacturing scale to ensure compliance with Good Manufacturing Practice (GMP) standards, assessing its applicability for commercial production. This will enhance the capacity to supply high-quality APIs consistently.
Background & Context
The biopharmaceutical market has been rapidly expanding in recent years, driving increased demand for novel modalities such as peptides and oligonucleotides. While these drugs demonstrate high specificity and efficacy in treating diseases, their manufacturing processes require specialized technologies distinct from those used for traditional small molecule drugs, due to the complexity of molecules and their instability to heat and pH. Maintaining quality while improving productivity has been a significant challenge, especially for thermolabile APIs. Asahi Kasei has extensive expertise in membrane separation technologies, and this FO-MD system leverages the company’s technical strengths. Its adoption by Peptistar, a pharmaceutical CDMO, contributes to overall manufacturing efficiency improvement and enhanced cost competitiveness within the supply chain.
Strategic Significance & Outlook
The installation of Asahi Kasei’s FO-MD system at Peptistar’s facility marks a crucial step towards improving the sustainability and efficiency of biopharmaceutical manufacturing processes. If this technology successfully completes its GMP production scale evaluation, it could be widely applied not only to peptides and oligonucleotides but also to other thermolabile biomolecules. This is expected to contribute to reduced manufacturing costs, shortened production lead times, and ultimately faster delivery of medicines to patients. This technological innovation will also foster green chemistry in the biopharmaceutical manufacturing industry and enhance supply chain resilience. Asahi Kasei plans to accelerate technology development and global expansion in this field.
Source: https://www.asahi-kasei.com/news/2026/e260625.html
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments